Retrophin Ups 2014, 2015 Revenue Guidance - Quick Facts

(RTTNews) - Retrophin, Inc. (RTRX) has increased its revenue forecast for both the year 2014 and 2015.

Looking ahead to 2014, the firm now sees revenue in the range of $19 million - $21 million, versus its prior range of $10 million - $12 million.

For 2015, revenue target is currently raised to $35 million - $40 million, from its previous $19 million - $21 million target.

Retrophin's Founder and Chief Executive, Martin Shkreli, said: "Reimbursement of Chenodal has remained robust, and initial efforts to find undiagnosed cerebrotendinous xanthomatosis (CTX) patients are promising."

On Friday, April 11, Retrophin received an update from RE-024 clinical investigators that, despite several investigator-sponsored IND filings for RE-024 in the U.S., the U.S. Food and Drug Administration or FDA has been unwilling to grant a clinical trial through this mechanism.